Unknown

Dataset Information

Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.


ABSTRACT:

Background

This study was designed to determine whether pramlintide added to insulin therapy reduced the risks associated with extreme blood glucose (BG) fluctuations in patients with type 1 diabetes.

Methods

Self-monitored BG (SMBG) records were retrospectively analyzed from a randomized, double-blind, placebo-controlled study of the effects of pramlintide on intensively treated patients with type 1 diabetes. Two groups--pramlintide (n=119), 30/60 microg administered subcutaneously at each meal, or placebo (n=129)--were matched by age, gender, and baseline hemoglobin A1C. Using SMBG, daily BG profiles, BG rate of change, and low and high BG indices (LBGI and HBGI, respectively) measuring the risk for hypoglycemia and hyperglycemia were calculated.

Results

Compared wi

SUBMITTER: Kovatchev BP 

PROVIDER: S-EPMC2979337 | biostudies-literature | 2008 Oct

REPOSITORIES: biostudies-literature